Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells

Jayaprakash Periasamy, Muthulakshmi Muthuswami, Vignesh Ramesh, Thangaselvam Muthusamy, Amrita Jain, Chandrabose Karthikeyan, Piyush Trivedi, Rayala Suresh Kumar, Paramasamy Gunasekaran, SunYoung Rha, Partick Tan, Ganesan Kumaresan

Research output: Contribution to journalArticle

Abstract

Despite being the leading cause of cancer death, targeted therapy for gastric cancer is yet to be established. Wnt/β-catenin signaling is highly deregulated in cancers of gastrointestinal origin including gastric cancers. Stabilization and deregulation of β-catenin occurs at multiple levels and so is being needed to identify a spectrum of Wnt inhibitors to combat deregulated Wnt signaling at the level of various targets and also in different combinations. We developed a luciferase reporter based gastric cancer cellular assay system for Wnt pathway modulator screening and identified nimesulide, a known COX-2 inhibitor as an inhibitor of Wnt/β catenin signaling pathway. Comprehensive signaling pathway profiling revealed that nimesulide could inhibit STAT3, IRF1 and RXR signaling apart from inhibiting Wnt/β-catenin-Myc-E2F signaling cascade. Nimesulide elicits a strong anti-proliferative effect by promoting cell cycle arrest in multiple gastric cancer cell lines. Inhibition of Wnt and STAT3 signaling are found to be COX-2 independent, while the inhibition of RXR and IRF1 pathways are due to the COX-2 inhibiting feature of nimesulide. While nimesulide is capable of activating Notch signaling in gastric cancer cells, celecoxib inhibits Wnt, Myc, E2F, RXR, STAT3, MAPK and Notch signaling pathways in gastric cancer cells. Signaling pathway focused analysis of gastric cancer transcriptome revealed that Wnt, STAT3, IRF1 and RXR signaling pathways are highly deregulated in majority of gastric tumors and indicates the potential of nimesulide and celecoxib class of drugs for targeted gastric cancer therapeutics. The differential inhibition of multiple signaling by nimesulide and celecoxib deserve further investigation.

Original languageEnglish
Pages (from-to)126-136
Number of pages11
JournalJournal of Cancer Science and Therapy
Volume5
Issue number4
DOIs
Publication statusPublished - 2013 May 30

Fingerprint

Celecoxib
nimesulide
Stomach Neoplasms
Catenins
Wnt Signaling Pathway
Gastrointestinal Neoplasms
Cyclooxygenase 2 Inhibitors
Cell Cycle Checkpoints
Luciferases
Transcriptome

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Periasamy, J., Muthuswami, M., Ramesh, V., Muthusamy, T., Jain, A., Karthikeyan, C., ... Kumaresan, G. (2013). Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells. Journal of Cancer Science and Therapy, 5(4), 126-136. https://doi.org/10.4172/1948-5956.1000198
Periasamy, Jayaprakash ; Muthuswami, Muthulakshmi ; Ramesh, Vignesh ; Muthusamy, Thangaselvam ; Jain, Amrita ; Karthikeyan, Chandrabose ; Trivedi, Piyush ; Kumar, Rayala Suresh ; Gunasekaran, Paramasamy ; Rha, SunYoung ; Tan, Partick ; Kumaresan, Ganesan. / Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells. In: Journal of Cancer Science and Therapy. 2013 ; Vol. 5, No. 4. pp. 126-136.
@article{885821ea06774623b9aa5f3f97d5c6bd,
title = "Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells",
abstract = "Despite being the leading cause of cancer death, targeted therapy for gastric cancer is yet to be established. Wnt/β-catenin signaling is highly deregulated in cancers of gastrointestinal origin including gastric cancers. Stabilization and deregulation of β-catenin occurs at multiple levels and so is being needed to identify a spectrum of Wnt inhibitors to combat deregulated Wnt signaling at the level of various targets and also in different combinations. We developed a luciferase reporter based gastric cancer cellular assay system for Wnt pathway modulator screening and identified nimesulide, a known COX-2 inhibitor as an inhibitor of Wnt/β catenin signaling pathway. Comprehensive signaling pathway profiling revealed that nimesulide could inhibit STAT3, IRF1 and RXR signaling apart from inhibiting Wnt/β-catenin-Myc-E2F signaling cascade. Nimesulide elicits a strong anti-proliferative effect by promoting cell cycle arrest in multiple gastric cancer cell lines. Inhibition of Wnt and STAT3 signaling are found to be COX-2 independent, while the inhibition of RXR and IRF1 pathways are due to the COX-2 inhibiting feature of nimesulide. While nimesulide is capable of activating Notch signaling in gastric cancer cells, celecoxib inhibits Wnt, Myc, E2F, RXR, STAT3, MAPK and Notch signaling pathways in gastric cancer cells. Signaling pathway focused analysis of gastric cancer transcriptome revealed that Wnt, STAT3, IRF1 and RXR signaling pathways are highly deregulated in majority of gastric tumors and indicates the potential of nimesulide and celecoxib class of drugs for targeted gastric cancer therapeutics. The differential inhibition of multiple signaling by nimesulide and celecoxib deserve further investigation.",
author = "Jayaprakash Periasamy and Muthulakshmi Muthuswami and Vignesh Ramesh and Thangaselvam Muthusamy and Amrita Jain and Chandrabose Karthikeyan and Piyush Trivedi and Kumar, {Rayala Suresh} and Paramasamy Gunasekaran and SunYoung Rha and Partick Tan and Ganesan Kumaresan",
year = "2013",
month = "5",
day = "30",
doi = "10.4172/1948-5956.1000198",
language = "English",
volume = "5",
pages = "126--136",
journal = "Journal of Cancer Science and Therapy",
issn = "1948-5956",
publisher = "OMICS Publishing Group",
number = "4",

}

Periasamy, J, Muthuswami, M, Ramesh, V, Muthusamy, T, Jain, A, Karthikeyan, C, Trivedi, P, Kumar, RS, Gunasekaran, P, Rha, S, Tan, P & Kumaresan, G 2013, 'Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells', Journal of Cancer Science and Therapy, vol. 5, no. 4, pp. 126-136. https://doi.org/10.4172/1948-5956.1000198

Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells. / Periasamy, Jayaprakash; Muthuswami, Muthulakshmi; Ramesh, Vignesh; Muthusamy, Thangaselvam; Jain, Amrita; Karthikeyan, Chandrabose; Trivedi, Piyush; Kumar, Rayala Suresh; Gunasekaran, Paramasamy; Rha, SunYoung; Tan, Partick; Kumaresan, Ganesan.

In: Journal of Cancer Science and Therapy, Vol. 5, No. 4, 30.05.2013, p. 126-136.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells

AU - Periasamy, Jayaprakash

AU - Muthuswami, Muthulakshmi

AU - Ramesh, Vignesh

AU - Muthusamy, Thangaselvam

AU - Jain, Amrita

AU - Karthikeyan, Chandrabose

AU - Trivedi, Piyush

AU - Kumar, Rayala Suresh

AU - Gunasekaran, Paramasamy

AU - Rha, SunYoung

AU - Tan, Partick

AU - Kumaresan, Ganesan

PY - 2013/5/30

Y1 - 2013/5/30

N2 - Despite being the leading cause of cancer death, targeted therapy for gastric cancer is yet to be established. Wnt/β-catenin signaling is highly deregulated in cancers of gastrointestinal origin including gastric cancers. Stabilization and deregulation of β-catenin occurs at multiple levels and so is being needed to identify a spectrum of Wnt inhibitors to combat deregulated Wnt signaling at the level of various targets and also in different combinations. We developed a luciferase reporter based gastric cancer cellular assay system for Wnt pathway modulator screening and identified nimesulide, a known COX-2 inhibitor as an inhibitor of Wnt/β catenin signaling pathway. Comprehensive signaling pathway profiling revealed that nimesulide could inhibit STAT3, IRF1 and RXR signaling apart from inhibiting Wnt/β-catenin-Myc-E2F signaling cascade. Nimesulide elicits a strong anti-proliferative effect by promoting cell cycle arrest in multiple gastric cancer cell lines. Inhibition of Wnt and STAT3 signaling are found to be COX-2 independent, while the inhibition of RXR and IRF1 pathways are due to the COX-2 inhibiting feature of nimesulide. While nimesulide is capable of activating Notch signaling in gastric cancer cells, celecoxib inhibits Wnt, Myc, E2F, RXR, STAT3, MAPK and Notch signaling pathways in gastric cancer cells. Signaling pathway focused analysis of gastric cancer transcriptome revealed that Wnt, STAT3, IRF1 and RXR signaling pathways are highly deregulated in majority of gastric tumors and indicates the potential of nimesulide and celecoxib class of drugs for targeted gastric cancer therapeutics. The differential inhibition of multiple signaling by nimesulide and celecoxib deserve further investigation.

AB - Despite being the leading cause of cancer death, targeted therapy for gastric cancer is yet to be established. Wnt/β-catenin signaling is highly deregulated in cancers of gastrointestinal origin including gastric cancers. Stabilization and deregulation of β-catenin occurs at multiple levels and so is being needed to identify a spectrum of Wnt inhibitors to combat deregulated Wnt signaling at the level of various targets and also in different combinations. We developed a luciferase reporter based gastric cancer cellular assay system for Wnt pathway modulator screening and identified nimesulide, a known COX-2 inhibitor as an inhibitor of Wnt/β catenin signaling pathway. Comprehensive signaling pathway profiling revealed that nimesulide could inhibit STAT3, IRF1 and RXR signaling apart from inhibiting Wnt/β-catenin-Myc-E2F signaling cascade. Nimesulide elicits a strong anti-proliferative effect by promoting cell cycle arrest in multiple gastric cancer cell lines. Inhibition of Wnt and STAT3 signaling are found to be COX-2 independent, while the inhibition of RXR and IRF1 pathways are due to the COX-2 inhibiting feature of nimesulide. While nimesulide is capable of activating Notch signaling in gastric cancer cells, celecoxib inhibits Wnt, Myc, E2F, RXR, STAT3, MAPK and Notch signaling pathways in gastric cancer cells. Signaling pathway focused analysis of gastric cancer transcriptome revealed that Wnt, STAT3, IRF1 and RXR signaling pathways are highly deregulated in majority of gastric tumors and indicates the potential of nimesulide and celecoxib class of drugs for targeted gastric cancer therapeutics. The differential inhibition of multiple signaling by nimesulide and celecoxib deserve further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84878178352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878178352&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000198

DO - 10.4172/1948-5956.1000198

M3 - Article

VL - 5

SP - 126

EP - 136

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

SN - 1948-5956

IS - 4

ER -

Periasamy J, Muthuswami M, Ramesh V, Muthusamy T, Jain A, Karthikeyan C et al. Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells. Journal of Cancer Science and Therapy. 2013 May 30;5(4):126-136. https://doi.org/10.4172/1948-5956.1000198